Christopher G. Bazewicz

Christopher G. Bazewicz, MD is an Assistant Professor in the Department of Dermatology at Penn State College of Medicine. He maintains clinical appointments across multiple Penn State Health facilities including the Penn State Cancer Institute, Penn State Health Dermatology, and the Lime Spring Outpatient Center in Lancaster.

Dr. Bazewicz completed his medical education at Penn State College of Medicine in 2019, followed by an Internal Medicine internship at University of Connecticut Health Center in 2020, and a Dermatology residency at Milton S. Hershey Medical Center in 2023.

• Medical School: Penn State College of Medicine (2019)
• Residency: Dermatology, Milton S. Hershey Medical Center (2023)
• Internship: Internal Medicine, University of Connecticut Health Center (2020)

His research spans dermatology, dermatopathology, and intersects with oncology and immunology. Analysis of his research fingerprint reveals expertise in Aldehyde Dehydrogenase 2 (ALDH2), Phenylalanine metabolism, Cyano compounds, Isotopomers, Dermatomyositis, and Protein Environment studies. His work contributes to UN Sustainable Development Goals related to health and well-being.

Dr. Bazewicz has published 23 research outputs between 2011-2025, with an h-index of 10 and 482 citations. His recent publications demonstrate a dual focus on dermatopathology case studies (presented as challenge-answer pairs in the American Journal of Dermatopathology) and molecular oncology research, particularly examining the p53 pathway's role in NK cell-mediated immunity. This reflects his bridging of clinical dermatology practice with cancer immunology research.

Dr. Bazewicz maintains an active clinical practice with high patient satisfaction ratings (4.9 out of 5 from 787 patient reviews). His clinical work spans general dermatology, dermatopathology, and cancer-related skin conditions through his appointments at the Penn State Cancer Institute. His research profile shows consistent scholarly output with publications appearing annually from 2011 through 2025, indicating sustained research productivity alongside clinical responsibilities.